Welcome to our dedicated page for REVIVE THERAPEUTICS news (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on REVIVE THERAPEUTICS stock.
Revive Therapeutics Ltd. develops specialty life sciences programs focused on infectious diseases and medical countermeasures. Company news commonly centers on Bucillamine, including intellectual-property filings, granted patent coverage, and research updates on its potential use in infectious diseases and nerve-agent exposure.
Revive updates also cover work with Defence R&D Canada – Suffield Research Centre, botanical research compounds, molecular hydrogen therapeutic programs, and financing activity. Capital-structure news includes private placements, debt settlement, unit issuances, common share purchase warrants, compensation options, and the use of proceeds for working capital and trade payables.
Revive Therapeutics, a specialty life sciences company, has provided an update on its research study evaluating Bucillamine for nerve agent exposure. This study, in collaboration with Defence R&D Canada – Suffield Research Centre, aims to find pharmacological treatments for nerve agent-induced brain injury. Control studies are underway, with data evaluation expected this month. Treatment studies will follow, and the research is slated to conclude by August 2024. The study compares Bucillamine, a potent antioxidant, to n-acetylcysteine (NAC) in enhancing the efficacy of GABA-mediating drugs like diazepam, potentially improving seizure control and reducing side effects. Promising results could pave the way for FDA and Health Canada approvals and may extend Bucillamine's use to treat traumatic brain injuries.
Revive Therapeutics announced updates on their Type C meeting with the FDA regarding a proposed clinical study of Bucillamine as a treatment for Long COVID. The FDA recommended submitting a new IND application, incorporating data from Revive's previous Phase 3 clinical trial on mild to moderate COVID-19. The FDA provided feedback on study design, population, and measures to assess therapeutic benefits. CEO Michael Frank expressed optimism about advancing Bucillamine's clinical development. The CDC estimates 7.5% of U.S. adults have Long COVID, costing up to $3.7 trillion. Revive aims to finalize their study protocol and submit the IND soon.
Results from a previous Phase 3 trial showed Bucillamine (600mg/day) prevented hospitalizations, while a lower dose (300mg/day) had one hospitalization compared to three in the placebo group. Bucillamine also improved oxygen saturation by 29.1% over placebo. These findings support further investigation of Bucillamine for Long COVID.
On June 10, 2024, Revive Therapeutics announced an update from the FDA regarding their Long COVID Diagnostic Product, the Revive LC POC Lateral Flow Test Kit. The FDA recommended the product follow the De Novo regulatory pathway, necessitating a clinical study for possible approval. CEO Michael Frank confirmed alignment with the FDA's recommendations and plans to discuss development and timelines with potential contract manufacturers. The product, developed under Revive Diagnostics, aims to detect long COVID via blood biomarkers identified by Dr. Douglas Fraser's research, recently published in Molecular Medicine. Currently, no FDA-approved diagnostic exists for long COVID, which affects at least 10% of SARS-CoV-2 infections and involves over 200 symptoms impacting multiple organ systems.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.